




Study Design



This post hoc analysis includes 60% (161/268) of randomized patients with mild psoriasis (IGA=2) at Week 16.



Conclusion



Patients with residual mild psoriasis who switched to guselkumab had greater improvements in skin disease than those who remained on ustekinumab through Week 52.

Results

